Randomized Phase 2 Trial Of Brentuximab Vedotin Or Crizotinib (Commercially Labeled) In Combination With Chemotherapy For Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)

Brief description of study

If your child has been newly diagnosed with Anaplastic Large Cell Lymphoma (ALCL), they may qualify to participate in a clinical trial evaluating the addition of either the drug brentuximab vedotin or the drug crizotinib to standard therapy for ALCL. The main goal of this study is to find out what the effects of adding brentuximab vedotin or crizotinib to standard chemotherapy drugs for Anaplastic Large Cell Lymphoma (ALCL) are and to evaluate ways that doctors can identify patients at high risk of recurrence (your cancer coming back).

Clinical Study Identifier: s14-01970
ClinicalTrials.gov Identifier: NCT01979536
Principal Investigator: Sharon L Gardner.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.